OYST News and Press, Oyster Point Pharma Inc. From 06/10/21

Collaboration plans for developing biological therapies potentially targeting multiple ophthalmic diseases utilizing APT’s PhageBank™ technology Oyster Point Pharma plans to discuss the potential for bacteriophage in the treatment of ophthalmic diseases a...

Introduction of proprietary ETF™ Gene Therapy and first gene candidate, nerve growth factor (NGF), to target Stages 2 and 3 Neurotrophic Keratopathy (NK) Preclinical study results from a 42-day proof-of-concept in vivo study demonstrated a single, intralacrimal gl...

Oyster Point Pharma, Inc. (OYST) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Daniel Lochner - Chief Financial Officer Jeffrey Nau - President and Chief Executive Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore - ...

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q1 2021 Earnings Call May 06, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q1 2021 Earnings Call Transcript...

Oyster Point Pharma (OYST): Q1 GAAP EPS of -$0.73 beats by $0.18.Press release. For further details see: Oyster Point Pharma EPS beats by $0.18

PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021 Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in Q4 2021, if approved by the FDA OLYMPIA Phase 2 Study on Track, with Planned Enrollment of the First Patient in 1H 2021 Co...

PRINCETON, N.J., May 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, announced today the presentation o...

PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced t...

PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced t...

The FDA has accepted Oyster Point Pharma's (OYST) New Drug Application ((NDA)) for OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.The PDUFA target action date is October 17.At present, FDA has stated that it does not intend to hold an advisory commi...